In this piece for The Conversation, Carlos López-Gómez from Cambridge's Institute for Manufacturing, discusses the role that small and medium-sized businesses might play in a post-Brexit economy.
Innovation is about the application of new ideas, discoveries and inventions. The innovative and entrepreneurial spirit of the members of the University of Cambridge is enshrined in the University’s mission statement to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence. The foundation for innovation is the steady supply of excellent ideas, of which there is an abundance at Cambridge. Ingenuity and creativity, alongside the fundamental research which underpins these ideas and combined with the constant exchange of ideas between academics and companies, governments and NGOs has been the recipe for this success.
Various mechanisms are in place to help our academics nurture future innovation. As well as dedicated departmental support structures, Cambridge Enterprise provides technology transfer, consultancy services and seed fund opportunities, and the Entrepreneurship Centre at Cambridge Judge Business School enables scientists, post-docs and researchers to translate innovation into reality through a range of practical programmes supporting entrepreneurs from start-up to scale-up.
Tony Kouzarides is passionate about ecosystems: well-balanced communities that flourish on mutual and dynamic interactions. But the ecosystems that excite him are not made up of plants, animals and environments. They’re made up of experts.
Nanotechnology is creating new opportunities for fighting disease – from delivering drugs in smart packaging to nanobots powered by the world’s tiniest engines.
The stirrings of a revolution are starting to ripple through hundreds of laboratories. It’s a revolution that aims to result in new medicines – faster and with fewer failures – and it’s being led by three UK universities and three global pharmaceutical companies.
Cambridge-based start-up company Bicycle Therapeutics has recently raised £40 million from a range of investors to bring its cancer drug candidates to clinical trials.